These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15867240

  • 1. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Kirpotin DB, Benz CC.
    Clin Cancer Res; 2005 May 01; 11(9):3392-401. PubMed ID: 15867240
    [Abstract] [Full Text] [Related]

  • 2. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R.
    Cancer Res; 2004 Sep 15; 64(18):6626-34. PubMed ID: 15374977
    [Abstract] [Full Text] [Related]

  • 3. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S.
    Novartis Found Symp; 2004 Sep 15; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [Abstract] [Full Text] [Related]

  • 4. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 15; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 5. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, Masuoka Y, Orita M, Sasamata M, Matsushime H, Furuichi K, Sakai T.
    Int J Oncol; 2008 Mar 15; 32(3):545-55. PubMed ID: 18292931
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB, Stewart CF, Houghton PJ.
    Clin Cancer Res; 2006 Jan 01; 12(1):223-34. PubMed ID: 16397046
    [Abstract] [Full Text] [Related]

  • 7. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):294-8. PubMed ID: 19906529
    [Abstract] [Full Text] [Related]

  • 8. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 9. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW.
    Cancer Res; 2006 Jul 01; 66(13):6732-40. PubMed ID: 16818648
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ.
    Biochem Biophys Res Commun; 2007 Apr 27; 356(1):233-8. PubMed ID: 17353008
    [Abstract] [Full Text] [Related]

  • 11. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 27; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 12. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
    Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC.
    Clin Cancer Res; 2001 Apr 27; 7(4):971-6. PubMed ID: 11309348
    [Abstract] [Full Text] [Related]

  • 13. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B, Ontoria JM, Cruz JC, Rowley M, Schultz-Fademrecht C, Steinkühler C, Jones P.
    Bioorg Med Chem Lett; 2009 Jun 01; 19(11):3081-4. PubMed ID: 19410459
    [Abstract] [Full Text] [Related]

  • 14. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.
    Eur J Haematol; 2006 Jan 01; 76(1):42-50. PubMed ID: 16343270
    [Abstract] [Full Text] [Related]

  • 15. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
    Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC.
    Cancer Res; 2008 Apr 01; 68(7):2375-83. PubMed ID: 18381445
    [Abstract] [Full Text] [Related]

  • 16. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors.
    Park R, Chang CC, Liang YC, Chung Y, Henry RA, Lin E, Mold DE, Huang RC.
    Clin Cancer Res; 2005 Jun 15; 11(12):4601-9. PubMed ID: 15958646
    [Abstract] [Full Text] [Related]

  • 17. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P.
    J Med Chem; 2003 Oct 09; 46(21):4609-24. PubMed ID: 14521422
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M.
    Cancer Res; 2006 May 15; 66(10):5409-18. PubMed ID: 16707469
    [Abstract] [Full Text] [Related]

  • 19. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 20. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR.
    Gastroenterology; 2006 Jun 01; 130(7):2130-44. PubMed ID: 16762634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.